Seer (SEER) Q2 2026 Earnings Call Transcript
Seer (SEER) reported Q2 2026 earnings, highlighting $209.5M in cash reserves and strategic investments, including share repurchases totaling 13.4M shares. The company emphasized scientific validation of its Proteograph Product Suite, with 95 publications supporting its platform. Key studies demonstrated Proteograph's superior performance in proteomics, reinforcing its value proposition and potential for revenue growth. Seer also announced plans to leverage AI for disease detection and highlighte



